Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.41 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.40 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | BLK | P51451 | 1/20 | 0.36 |
| ▸ | BMX | P51813 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484367 | 0.86 | EGFR (0.51) | EGFRNUAK2NUAK1ERBB2JAK3 | |
| SCHEMBL29538509 | 0.85 | JAK3 (0.46) | EGFRNUAK1ERBB2JAK3JAK2 | |
| SCHEMBL21758097 | 0.85 | EGFR (0.39) | EGFRNUAK2NUAK1ERBB2JAK3 | |
| SCHEMBL21515827 | 0.82 | EGFR (0.52) | EGFRNUAK1ERBB2JAK3JAK2 | |
| SCHEMBL21484319 | 0.80 | EGFR (0.39) | EGFRCTSC | |
| SCHEMBL21751158 | 0.80 | EGFR (0.45) | EGFRNUAK2NUAK1ERBB2JAK3 | |
| SCHEMBL21484378 | 0.80 | EGFR (0.45) | EGFRNUAK2NUAK1ERBB2JAK3 | |
| SCHEMBL21484369 | 0.78 | KIT (0.33) | EGFRNUAK1ERBB2JAK3JAK2 | |
| SCHEMBL21516142 | 0.78 | EGFR (0.37) | EGFRNUAK1ERBB2JAK3JAK2 | |
| SCHEMBL21484372 | 0.76 | PIM1 (0.32) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | EGFR 1705/4885NUAK2 2479/4885NUAK1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.